Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy - The CHECK-UP study: A randomized controlled trial

Archives of Internal Medicine

Volumn 167, Issue 21, 2007, Pages 2296-2303

  Grover, Steven A ^a,b,d   Lowensteyn, Ilka ^a,b   Joseph, Lawrence ^a,b   Kaouache, Mohammed ^a,b   Marchand, Sylvie ^a,b   Coupal, Louis ^a,b   Boudreau, Ghislain ^c  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c PFIZER INC   (United States)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTILIPEMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; KNOWLEDGE; LIFE STYLE; LIPIDS; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 36549045979     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.21.2296     Document Type: Article

References (36)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001-1009.
3. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
5. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696.
6. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
7. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24(17):1601-1610.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
9. Jackson R, Lawes C, Bennet D, Milne R, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365(9457):434-441.
10. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459-467.
11. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S; HERS Research Group. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/Progestin Replacement Study (HERS). JAMA. 1997;277(16):1281- 1286.
12. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med. 1996;100(2):197-204.
13. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to national cholesterol education program guidelines for patients with coronary heart disease. Arch Intern Med. 1998;158(11):1238-1244.
14. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100(6):605-610.
15. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461.
16. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462-467.
17. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18):1458-1462.
18. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164(4):208-211.
19. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332(17):1125-1131.
20. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA. 2002;288(19):2469-2475.
21. Holman H. Chronic disease: the need for a new clinical education. JAMA. 2004;292(9):1057-1059.
22. Deber RB, Kraetchmer N, Irvine J. What role do patients wish to play in treatment decision making? Arch Intern Med. 1996;156(13):1414-1420.
23. Braddock CH, Edwards KA, Hassenberg NM, Laidley TL, Levinson W. Informed decision making in outpatient practice: time to get back to basics. JAMA. 1999;282(24):2313-2320.
24. Barry MJ. Involving patients in medical decisions: how can physicians do better? JAMA. 1999;282(24):2356-2357.
25. Fodor JG, Frohlich JJ, Genest JJ Jr, McPherson PR; Working Group on Hypercholesterolemia and Other Dyslipidemia. Recommendations for the management and treatment of dyslipidemia. CMAJ. 2000;162(10):1441-1447.
26. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med. 1998;158(6):655-662.
27. Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupal L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease: estimating changes in life expectancy and morbidity. JAMA. 1992;267(6):816-822.
28. Grover SA, Lowensteyn I, Esrey K, Steinert Y, Joseph L, Abrahamowicz M. How accurately do Canadian physicians assess the coronary risk of their patients? the preliminary results of the Coronary Health Assessment Study (CHAS). BMJ. 1995;310(6985):975-978.
29. MacLean DR, Petrasovits A, Nargundkar M, et al; Canadian Heart Health Surveys Research Group. Canadian heart health surveys: a profile of cardiovascular risk: survey methods and data analysis. CMAJ. 1992;146(11):1969-1974.
30. Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover SA. Can computerized risk profiles help patients improve their coronary risk? the results of the Coronary Health Assessment Study (CHAS). Prev Med. 1998;27(5, pt 1):730-737.
31. Joseph L, du Berger R, Bélisle P. Bayesian and mixed Bayesian/likelihood criteria for sample size determination. Stat Med. 1997;16(7):769-781.
32. Lee KJ, Thompson SG. Clustering by health professional in individually randomised trials. BMJ. 2005;330(7483):142-144.
33. Sullivan LM, Dukes KA, Losina E. Tutorial in biostatistics: an introduction to hierarchical linear modelling. Stat Med. 1999;18(7):855-888.
34. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423-1429.
35. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152-160.
36. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582-587.